再生元制药公司宣布，美国食品药品监督管理局(FDA)已批准扩大其药物Evkeeza的适应症范围，该药物现可用于治疗更年轻的同型胞质高胆固醇血症(HoFH)患者。
这一批准标志着Evkeeza治疗范围的重要扩展，将为更多年轻患者提供治疗选择。同型胞质高胆固醇血症是一种罕见的遗传性疾病，患者体内胆固醇水平极高，需要专门的治疗方案。
FDA此次批准扩大适应症，意味着Evkeeza在治疗这一罕见疾病方面的应用将更加广泛，有望惠及更多需要治疗的年轻患者群体。
再生元制药公司宣布，美国食品药品监督管理局(FDA)已批准扩大其药物Evkeeza的适应症范围，该药物现可用于治疗更年轻的同型胞质高胆固醇血症(HoFH)患者。
这一批准标志着Evkeeza治疗范围的重要扩展，将为更多年轻患者提供治疗选择。同型胞质高胆固醇血症是一种罕见的遗传性疾病，患者体内胆固醇水平极高，需要专门的治疗方案。
FDA此次批准扩大适应症，意味着Evkeeza在治疗这一罕见疾病方面的应用将更加广泛，有望惠及更多需要治疗的年轻患者群体。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.